Physician profile
Melissa L Barnett
NPI 1669450425
$49,840.80
in general payments reported to CMS, 2019-2025
22 companies · $5,462 in 2025
The $5,462 reported for 2025 was more than what 99% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,920 · 2022: $5,555 · 2023: $19K · 2024: $16K · 2025: $5,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,400 · Food and Beverage: $2,151 · Honoraria: $1,575 · Travel and Lodging: $200 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,941.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,400.00 |
| Food and Beverage | $2,150.75 |
| Honoraria | $1,575.00 |
| Travel and Lodging | $200.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $35,261.01 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $11,823.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,081.84 | 2021-2022 | |
| Astellas Pharma US INC | $441.25 | 2024-2025 | Veozah |
| Abbvie INC. | $408.91 | 2021-2025 | |
| Exeltis, USA INC. | $197.54 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $89.74 | 2022-2024 | |
| Aspira Women'S Health INC | $82.54 | 2021 | |
| Millicent US INC | $82.46 | 2025 | Intrarosa, Femlyv, Femring |
| Hologic Sales and Service, LLC | $64.70 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Daiichi Sankyo INC. | $58.98 | 2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.77 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $30.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.11 | 2021-2022 | |
| Biogen, INC. | $27.09 | 2024 | Zurzuvae |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $18.13 | 2024 | Deknatel |
| Pfizer INC. | $15.66 | 2025 | |
| Therapeuticsmd, INC. | $15.09 | 2021 | |
| Amgen INC. | $14.75 | 2025 | Evenity |
| Avion Pharmaceuticals | $14.69 | 2022 | |
| Shield Therapeutics INC | $13.17 | 2023 | Accrufer |
| Lupin INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.